Oral anticoagulants (OACs), which can either be vitamin K antagonists (VKAs; e.g., warfarin) or novel oral anticoagulants (NOACs; e.g., apixaban, dabigatran, edoxaban, rivaroxaban), are used for AF treatment, whereas dual antiplatelet therapy (DAPT) consisting of aspirin and P2Y12 inhibitors (e.g., clopidogrel) is used for ACS treatment [1, 4, 12, 13]. The gene discussed is P2RY12; the disease is atrial fibrillation.